A new anti-cancer drug can be made from ‘cancer cells’

A new type of anti-nausea drug developed in China has been shown to be as effective against cancer cells as chemotherapy.

The drug, which is being developed at the University of Tianshi in China, works by targeting the proteins that cause tumours to form.

“In the new drug, we’ve found that it’s possible to remove some of the abnormal proteins that are present in the cancer cells,” said Dr Richard McElroy, the lead researcher of the new study.

“These proteins are part of the tumour protein, which makes it difficult for cancer cells to attack the cancer,” Dr McElroys research assistant at the university.

“By targeting these proteins, we can remove the proteins from the tumours, so that the cancer can attack it,” Dr Dr McEarls told the ABC.

“So we’re not only removing a number of proteins, but we’re also able to remove many of the normal proteins that we normally think are part and parcel of cancer cells.”

Dr McElroys study involved developing a drug that targets the proteins, called TGF-beta1, that cause the development of cancer.

“The problem is that TGFs are very complex proteins, and it’s really difficult to isolate them, so we had to make these compounds,” Dr McNealys said.

“We have been trying to find a way of making a drug which targets these proteins.”

And so we were able to develop the first drug that did that.

“The researchers have now tested the drug on mice, but have not yet given it to humans.

Dr McEarys research team is now working to develop a new drug for cancer, called GCL-4, which will be more potent and also safer.”

It’s not just going to treat cancer cells, it’s going to target cancer cells from different parts of the body,” Dr McHale said.

He said while the drug is already effective, it was still not ready for humans to use.”

There’s some really promising work that we’re doing with this, but it’s a very long way off,” Dr McLayes said.

Topics:cancer,medical-research,medicines-and-oils,drugs-and/or-technology,human-interest,china,australiaContact Andrew McElmoreMore stories from New South Wales